X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC PHARMA NOVARTIS/
ALEMBIC PHARMA
 
P/E (TTM) x 361.2 29.0 1,245.2% View Chart
P/BV x 17.8 6.6 268.7% View Chart
Dividend Yield % 1.6 0.7 228.0%  

Financials

 NOVARTIS   ALEMBIC PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ALEMBIC PHARMA
Mar-16
NOVARTIS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs982792 124.0%   
Low Rs556443 125.6%   
Sales per share (Unadj.) Rs252.9167.0 151.4%  
Earnings per share (Unadj.) Rs62.138.2 162.8%  
Cash flow per share (Unadj.) Rs63.342.0 150.7%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.30.6 200.7%  
Book value per share (Unadj.) Rs363.684.9 428.3%  
Shares outstanding (eoy) m31.96188.52 17.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.03.7 82.3%   
Avg P/E ratio x12.416.2 76.5%  
P/CF ratio (eoy) x12.214.7 82.7%  
Price / Book Value ratio x2.17.3 29.1%  
Dividend payout %16.110.5 153.5%   
Avg Mkt Cap Rs m24,580116,383 21.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m1,8014,214 42.7%   
Avg. sales/employee Rs Th10,748.9NM-  
Avg. wages/employee Rs Th2,395.2NM-  
Avg. net profit/employee Rs Th2,641.1NM-  
INCOME DATA
Net Sales Rs m8,08331,487 25.7%  
Other income Rs m82955 1,505.3%   
Total revenues Rs m8,91331,542 28.3%   
Gross profit Rs m23410,060 2.3%  
Depreciation Rs m37722 5.1%   
Interest Rs m237 4.9%   
Profit before tax Rs m1,0259,356 11.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m17-2 -1,113.3%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7522,160 34.8%   
Profit after tax Rs m1,9867,194 27.6%  
Gross profit margin %2.931.9 9.1%  
Effective tax rate %73.423.1 317.7%   
Net profit margin %24.622.8 107.5%  
BALANCE SHEET DATA
Current assets Rs m12,67815,066 84.2%   
Current liabilities Rs m2,4337,674 31.7%   
Net working cap to sales %126.723.5 539.9%  
Current ratio x5.22.0 265.4%  
Inventory Days Days3367 48.8%  
Debtors Days Days2241 55.3%  
Net fixed assets Rs m698,237 0.8%   
Share capital Rs m160377 42.4%   
"Free" reserves Rs m11,46015,416 74.3%   
Net worth Rs m11,62116,005 72.6%   
Long term debt Rs m00-   
Total assets Rs m14,40024,594 58.5%  
Interest coverage x570.5255.2 223.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.3 43.8%   
Return on assets %13.829.4 47.0%  
Return on equity %17.144.9 38.0%  
Return on capital %23.658.7 40.2%  
Exports to sales %0.755.7 1.3%   
Imports to sales %18.610.4 178.3%   
Exports (fob) Rs m6017,551 0.3%   
Imports (cif) Rs m1,5033,283 45.8%   
Fx inflow Rs m18617,811 1.0%   
Fx outflow Rs m1,8215,318 34.2%   
Net fx Rs m-1,63512,493 -13.1%   
CASH FLOW
From Operations Rs m2,5319,304 27.2%  
From Investments Rs m-8,270-3,105 266.4%  
From Financial Activity Rs m-386-1,959 19.7%  
Net Cashflow Rs m-6,1254,240 -144.4%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 2.9 69.0%  
FIIs % 1.6 9.1 17.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 13.9 154.7%  
Shareholders   41,647 49,328 84.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 23, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS